BioAnaLab Report issue

For profit Phase 3
Founded: Oxford United Kingdom (2002)
Status: Acquired by Millipore (2009) → now Merck Serono (2006)

Organization Overview

First Clinical Trial
2008
NCT01077908
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (1)

cmv-specific t-cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cytomegalovirus Infections (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1